Role of fibrates in the management of hypertriglyceridemia

Am J Cardiol. 1999 May 13;83(9B):30F-35F. doi: 10.1016/s0002-9149(99)00270-2.

Abstract

Elevated plasma triglyceride levels are increasingly recognized as a risk factor for cardiovascular disease. Fibric acid derivatives (fibrates) substantially decrease triglyceride levels and have been demonstrated to decrease clinical cardiovascular events in some trials. Ongoing research will elucidate the molecular mechanisms by which fibrates modify lipoprotein metabolism, clarify their use in combination with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), and determine their role in the prevention of cardiovascular events.

Publication types

  • Review

MeSH terms

  • Anticholesteremic Agents / therapeutic use
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control
  • Drug Therapy, Combination
  • Female
  • Gemfibrozil / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypertriglyceridemia / complications
  • Hypertriglyceridemia / drug therapy*
  • Hypolipidemic Agents / therapeutic use*
  • Lovastatin / therapeutic use
  • Male
  • Randomized Controlled Trials as Topic
  • Risk Factors

Substances

  • Anticholesteremic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Lovastatin
  • Gemfibrozil